| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442804 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
Although generally well tolerated, dovitinib has very limited single-agent activity in patients with previously treated advanced UC, regardless of FGFR3 mutation status. clinicaltrials.gov NCT00790426.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Matthew I. Milowsky, Christian Dittrich, Ignacio Durán, Satinder Jagdev, Frederick E. Millard, Christopher J. Sweeney, Dean Bajorin, Linda Cerbone, David I. Quinn, Walter M. Stadler, Jonathan E. Rosenberg, Melissa Lochheed, Paramita Sen,